Crinetics Pharmaceuticals
CRNX
181 hedge funds and large institutions have $2.54B invested in Crinetics Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 75 increasing their positions, 58 reducing their positions, and 23 closing their positions.
89% more call options, than puts
Call options by funds: $22.4M | Put options by funds: $11.9M
48% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 23
29% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 58
24% more capital invested
Capital invested by funds: $2.04B → $2.54B (+$499M)
6% more funds holding
Funds holding: 171 → 181 (+10)
3.15% more ownership
Funds ownership: 103.59% → 106.74% (+3.2%)
31% less funds holding in top 10
Funds holding in top 10: 13 → 9 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$58.4M |
| 2 |
Jennison Associates
New York
|
+$34.2M |
| 3 |
Morgan Stanley
New York
|
+$24.1M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$23.8M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$23.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$37.9M |
| 2 |
O
OrbiMed
New York
|
-$37.7M |
| 3 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$36.6M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$24.8M |
| 5 |
CC
Commodore Capital
New York
|
-$14.9M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
201
Belvedere Trading
Chicago,
Illinois
| – | -$101K | -3,404 | Closed |
|
|
HHGC
202
Hunting Hill Global Capital
New York
| – | -$52.6K | -1,769 | Closed |
|
203
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | -$2K | -60 | Closed |
|
CRNX Hedge Fund Activity: Q4 2023 in Review
181 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q4 2023, worth a combined $2.54B — up 24% from $2.04B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new CRNX positions and 23 closed out — a net gain of 11 holders — while 75 added to existing stakes and 58 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $58.4M. The largest seller was Bain Capital Life Sciences Investors, exiting entirely with an estimated $37.9M sold.
- 181 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q4 2023, up from 171 in Q3 2023.
- Funds reported $2.54B of Crinetics Pharmaceuticals stock for Q4 2023, up 24% quarter-over-quarter.
- 34 funds opened new Crinetics Pharmaceuticals positions in Q4 2023 and 23 closed out, a net change of +11 holders.
- The largest Crinetics Pharmaceuticals buyer in Q4 2023 was Fidelity Investments, an estimated $58.4M added.
- The largest Crinetics Pharmaceuticals seller in Q4 2023 was Bain Capital Life Sciences Investors, an estimated $37.9M sold.
Based on aggregated 13F filings for Q4 2023.